254 related articles for article (PubMed ID: 30282671)
1. Somatic Mutations and Immune Alternation in Rectal Cancer Following Neoadjuvant Chemoradiotherapy.
Ji D; Yi H; Zhang D; Zhan T; Li Z; Li M; Jia J; Qiao M; Xia J; Zhai Z; Song C; Gu J
Cancer Immunol Res; 2018 Nov; 6(11):1401-1416. PubMed ID: 30282671
[TBL] [Abstract][Full Text] [Related]
2. A combination of stromal PD-L1 and tumoral nuclear β-catenin expression as an indicator of colorectal carcinoma progression and resistance to chemoradiotherapy in locally advanced rectal carcinoma.
Takahashi H; Watanabe H; Hashimura M; Matsumoto T; Yokoi A; Nakagawa M; Ishibashi Y; Ito T; Ohhigata K; Saegusa M
J Pathol Clin Res; 2022 Sep; 8(5):458-469. PubMed ID: 35762092
[TBL] [Abstract][Full Text] [Related]
3. Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer.
Baretti M; Zhu Q; Fu W; Meyer J; Wang H; Anders RA; Azad NS
Oncotarget; 2022; 13():907-917. PubMed ID: 35937503
[TBL] [Abstract][Full Text] [Related]
4. The prognostic role of TCF4 expression in locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy.
Dou X; Wang R; Meng X; Yan H; Jiang S; Zhu K; Xu X; Chen D; Song X; Mu D
Cancer Biomark; 2015; 15(2):181-8. PubMed ID: 25519018
[TBL] [Abstract][Full Text] [Related]
5. An Immune-Related Gene Signature for Predicting Neoadjuvant Chemoradiotherapy Efficacy in Rectal Carcinoma.
Qian L; Lai X; Gu B; Sun X
Front Immunol; 2022; 13():784479. PubMed ID: 35603163
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer patients: a systematic review.
Yang L; Cui X; Wu F; Chi Z; Xiao L; Wang X; Liang Z; Li X; Yu Q; Lin X; Gao C
Front Immunol; 2024; 15():1392499. PubMed ID: 38846948
[TBL] [Abstract][Full Text] [Related]
7. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
[TBL] [Abstract][Full Text] [Related]
8. FOSL2 promotes intertumoral infiltration of T cells and increases pathological complete response rates in locally advanced rectal cancer patients.
Xu K; Yin X; Zhou B; Zheng X; Wang H; Chen J; Cai X; Gao H; Xu X; Wang L; Shen L; Guo T; Zheng S; Li B; Shao Y; Wang J
Cancer Lett; 2023 May; 562():216145. PubMed ID: 36997107
[TBL] [Abstract][Full Text] [Related]
9. Identification of four immune subtypes in locally advanced rectal cancer treated with neoadjuvant chemotherapy for predicting the efficacy of subsequent immune checkpoint blockade.
He L; Jin M; Jian D; Yang B; Dai N; Feng Y; Xiao H; Wang D
Front Immunol; 2022; 13():955187. PubMed ID: 36238279
[TBL] [Abstract][Full Text] [Related]
10. Rectal cancer sub-clones respond differentially to neoadjuvant therapy.
Frydrych LM; Ulintz P; Bankhead A; Sifuentes C; Greenson J; Maguire L; Irwin R; Fearon ER; Hardiman KM
Neoplasia; 2019 Oct; 21(10):1051-1062. PubMed ID: 31521947
[TBL] [Abstract][Full Text] [Related]
11. RAD18 may function as a predictor of response to preoperative concurrent chemoradiotherapy in patients with locally advanced rectal cancer through caspase-9-caspase-3-dependent apoptotic pathway.
Yan X; Chen J; Meng Y; He C; Zou S; Li P; Chen M; Wu J; Ding WQ; Zhou J
Cancer Med; 2019 Jun; 8(6):3094-3104. PubMed ID: 31033216
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer.
Seo I; Lee HW; Byun SJ; Park JY; Min H; Lee SH; Lee JS; Kim S; Bae SU
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33692216
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
[No Abstract] [Full Text] [Related]
14. Novel biomarkers to predict treatment response and prognosis in locally advanced rectal cancer undergoing neoadjuvant chemoradiotherapy.
Guan B; Xu M; Zheng R; Guan G; Xu B
BMC Cancer; 2023 Nov; 23(1):1099. PubMed ID: 37953237
[TBL] [Abstract][Full Text] [Related]
15. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
16. Tumor mutation burden in blood predicts benefit from neoadjuvant chemo/radiotherapy in locally advanced rectal cancer.
Ji D; Zhang D; Zhan T; Jia J; Han W; Li Z; Li M; Song C; Wang J; Gu J
Genomics; 2021 Jan; 113(1 Pt 2):957-966. PubMed ID: 33129922
[TBL] [Abstract][Full Text] [Related]
17. ceRNA Networks: The Backbone Role in Neoadjuvant Chemoradiotherapy Resistance/Sensitivity of Locally Advanced Rectal Cancer.
He L; Chang H; Qi Y; Zhang B; Shao Q
Technol Cancer Res Treat; 2021; 20():15330338211062313. PubMed ID: 34908512
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers.
Chiang SF; Huang CY; Ke TW; Chen TW; Lan YC; You YS; Chen WT; Chao KSC
Cancer Immunol Immunother; 2019 Feb; 68(2):283-296. PubMed ID: 30448924
[TBL] [Abstract][Full Text] [Related]
19. A good preoperative immune prognostic index is precits a better prognosis for locally advanced rectal cancer patients with ypTNM stage II who underwent radical resection after neoadjuvant chemoradiotherapy.
Li S; Wang Y; Cai H; Pan Z; Guan G
Int J Colorectal Dis; 2023 Jul; 38(1):184. PubMed ID: 37395868
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients.
Lopes-Ramos CM; Habr-Gama A; Quevedo Bde S; Felício NM; Bettoni F; Koyama FC; Asprino PF; Galante PA; Gama-Rodrigues J; Camargo AA; Perez RO; Parmigiani RB
BMC Med Genomics; 2014 Dec; 7():68. PubMed ID: 25496125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
